Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drug

Beconase Aq(Beclomethasone Dipropionate)GSK plc logoGSK

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by GSK plc

$130K

Medicare cost, 2024

Medicare drug plans spent $129,984 on Beconase Aq (beclomethasone dipropionate) in 2024, for 349 prescriptions and refills filled by 270 patients. Spending fell 90% from 2023 to 2024. California accounts for the most spending ($12,323, 9% of the total). It is made by GSK plc (GSK).

Medicare cost, 2024

$130K

-89.8% from 2023

Prescriptions

349

$372.45 per claim

Patients

270

272 prescribers

Total spending, 2024

$130K

$481.42 per patient

Questions and answers

How much does Medicare spend on Beconase Aq?

Medicare prescription drug plans paid $130K for Beconase Aq in 2024, for 349 prescriptions and refills to 270 patients (down 89.8% from 2023). The average cost per claim was $372.45.

Which state spends the most on Beconase Aq?

California had the highest Medicare cost for Beconase Aq in 2024: $12K for 36 claims, followed by Massachusetts ($10K).

Who makes Beconase Aq?

Beconase Aq is made by GSK plc (GSK), listed in the Medicare spending data as Glaxosmithkline.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Beconase Aq was $130K in 2024, after a high of $1.9M in 2020.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Prescriber data by year

YearPrescribersClaimsPatientsCost
20221,2063,2311,124$1.3M
20231,0913,0651,013$1.3M
2024272349270$130K

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
GlaxosmithklineGSK logoGSK349$130K

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube